How to Restart Your Peptide Program After the FDA Reclassification — A Clinic Compliance Checklist

By GlowRoute Editorial Team | April 4, 2026

---

With the FDA moving to lift restrictions on 14 compounded peptides, thousands of medspas that paused or eliminated their peptide programs in 2023-2024 are asking: How do we restart — compliantly?

This guide provides the exact checklist clinic operators need before flipping the peptide switch back on.

---

⚠️ Critical First Step: Don't Jump the Gun

FDA confirmation is "expected" but not yet official as of April 4, 2026.

The FDA has announced the reclassification publicly, but the final written rule hasn't been published in the Federal Register. Before restarting peptide programs:

• [ ] Monitor FDA announcements for final rule publication (expected within 30-90 days)
• [ ] Do NOT start compounding until the final rule is official
• [ ] Do prepare now — have protocols reviewed, staff trained, pharmacy partnerships in place

Why this matters: Restarting before final FDA clarification could expose your clinic to regulatory risk.

---

The 6-Step Restart Checklist

Step 1: Compliant Prescription Protocol ✓

Requirements:

• [ ] Individual patient prescriptions — No standing orders or bulk dispensing
• - Every patient must have a unique Rx from a licensed provider (MD, DO, NP, PA licensed in your state)
• - Patient-specific: "BPC-157 100mg, IM injection, 1-2x/week" (not "peptide therapy per protocol")
• [ ] Medical necessity documentation — Chart note must document why peptide is appropriate for this patient
• - Patient history review
• - Indication for therapy (joint pain, recovery, anti-aging, etc.)
• - Risk-benefit discussion documented
• - Patient education and informed consent signed
• [ ] Prescription controls — Rx tracking and refill limits
• - Use state's prescription tracking system (Florida PDMP, Arizona PDMP, etc.)
• - Document prescriber (NP/PA credentials verified)
• - Refill policy clearly documented

Sample prescription language: ` Rx: BPC-157 (peptide) 100mg Route: Intramuscular injection Frequency: Twice weekly for 8 weeks, then reassess Prescriber: [Licensed MD/DO/NP/PA name], License #___ Patient: [Full name, DOB] Date: [Date] Signature: [Provider] `

Step 2: Licensed Pharmacy Verification ✓

Requirements:

• [ ] 503B licensed compounding pharmacy ONLY
• - Verify pharmacy DEA license and compounding certification
• - Confirm they're on FDA's list of registered compounding pharmacies
• - Request their quality control protocols (sterility testing, potency assurance)
• [ ] Certificate of Analysis (CoA) for every batch
• - Proof of purity, sterility, potency
• - Batch testing results (endotoxin testing, microbial testing)
• - Expiration dating and storage requirements
• [ ] Written agreement with pharmacy
• - Service level agreement (SLA)
• - Quality standards and guarantees
• - Adverse event reporting procedures
• - Escalation process if product concerns arise

Red flag pharmacies: - ❌ No valid DEA/state licensing - ❌ Can't provide CoA on request - ❌ Pricing suspiciously low (<$50/vial) - ❌ No quality control protocols documented

Recommended verified pharmacies: - Emerson Radio Pharmacy (Chicago-based 503B, PCAB accredited) - Belmar Pharmacy (Colorado-based, specialty peptide compounding) - Gateway Pharmacy (Texas-based 503B, peptide specialist)

Step 3: Medical Director Oversight ✓

Requirements:

• [ ] Active medical director on staff or via contract
• - Licensed MD/DO with current state license
• - No expired or lapsed credentials
• - Available for consultation on patient cases
• [ ] Delegation agreement updated and signed
• - Written delegation from medical director to NP/PA for peptide administration
• - Scope clearly defined (which peptides, dosing, patient populations)
• - Review schedule (quarterly minimum)
• [ ] Supervision documentation — Maintain logs
• - Date/time of medical director oversight
• - Patient reviewed and approved (signature or electronic attestation)
• - Dosing verified
• - Any adverse events documented

Sample delegation language: ` DELEGATION AGREEMENT

Medical Director: [MD name], License #___ Delegated Provider: [NP name], License #___ Date: [Effective date]

SCOPE: BPC-157, TB-500, Ipamorelin peptide administration AUTHORIZATION: Medical director delegates peptide administration to [NP] per following protocol: - Initial patient evaluation by medical director required - Subsequent dosing adjustments per standing protocol reviewed by MD quarterly - All patients reviewed by MD within 7 days of administration

SUPERVISION: Medical director available for consultation at [phone/email] REVIEW: Quarterly review of all patient records, adverse events, and outcomes

Signatures: [MD] [NP] [Date] `

Step 4: State-Specific Consent Forms & Education ✓

Requirements:

• [ ] Informed consent form signed before every patient course
• - Must include:
• - Clear explanation: "These peptides are NOT FDA-approved; they are legal to compound and use with physician oversight"
• - Realistic benefits ("may help with recovery, joint health, anti-aging")
• - Potential risks and side effects
• - Alternative treatments available
• - Patient questions answered before signature
• [ ] Regulatory-compliant language
• - Use phrase: "Category 1 compounded peptide" (not "FDA-approved")
• - Avoid claims like: "clinically proven," "FDA endorsed," "medically necessary" (too strong)
• - Use cautious language: "emerging research suggests," "may help," "preliminary data shows"
• [ ] Patient education materials
• - Written handout on peptide therapy basics
• - Storage and administration instructions
• - Side effect monitoring guide
• - When to seek emergency care (allergic reactions, unusual symptoms)

Example consent form section: ` PATIENT INFORMED CONSENT FOR PEPTIDE THERAPY

I understand that: 1. Peptide therapy is an emerging treatment not approved by the FDA 2. These peptides are compounded at licensed pharmacies per my physician's prescription 3. Potential benefits include [list specific expectations] 4. Potential risks include [list known risks] 5. My physician will monitor my response and adjust therapy as needed 6. I can stop therapy at any time

I have reviewed these risks and benefits and choose to proceed.

Patient Signature: ________ Date: ________ Witness: ________ Physician Signature: ________ Date: ________ `

Step 5: Marketing Compliance (Critical!) ✓

• [ ] Never use these phrases:
• - ❌ "FDA-approved peptides"
• - ❌ "Clinically proven" (unless you have peer-reviewed data)
• - ❌ "Cure for [disease]"
• - ❌ "Guaranteed results"
• - ❌ "Better than [competitor product]"
• [ ] Use these instead:
• - ✅ "Peptide therapy available by prescription"
• - ✅ "Emerging research suggests..."
• - ✅ "May help support..."
• - ✅ "Results vary by individual"
• - ✅ "Physician-supervised protocols"
• [ ] Social media guidelines
• - No before/afters claiming "peptide therapy" unless compliant (hard to do)
• - Patient testimonials must include disclaimer
• - Don't make disease claims ("treats arthritis," "cures aging")
• - Link all content to compliant website disclaimer

Step 6: Documentation & Adverse Event Reporting ✓

Record keeping requirements:

• [ ] Treatment records (7+ year retention)
• - Date of administration
• - Peptide name, dose, lot number
• - Provider administering (signature)
• - Patient response and side effects noted
• - Medical director review and sign-off

• [ ] Adverse event tracking
• - Any unusual reactions, allergies, or complications documented
• - Reported to medical director within 24 hours
• - Reported to pharmacy within 48 hours
• - If serious, consider FDA MedWatch reporting (voluntary, but shows good faith)

• [ ] Patient follow-up schedule
• - Initial visit: Baseline assessment, labs if indicated
• - Week 2: Phone check-in (side effects, questions)
• - Week 4: In-person or virtual check-in (response assessment)
• - Week 8: Reassessment and decision to continue, modify, or discontinue

Sample adverse event log: ` ADVERSE EVENT REPORT

Date: _____ Patient: _____ Peptide: _____ Dose: _____ Event Description: [Describe incident] Severity: Mild / Moderate / Severe Provider Response: [What was done] Medical Director Notified: [Date/time] Pharmacy Notified: [Date/time] Signature: _____ Date: _____ `

---

The GlowRoute Verification Advantage

Clinics that restart peptide programs correctly and document it well can become GlowRoute-verified "Peptide Clinics" — a high-demand search category.

Benefits of GlowRoute verification: - Higher visibility in search results for "peptide clinic near me" - Trust badge on your listing - Qualification for referral partnerships with orthopedic surgeons and longevity clinics - Lead generation from high-intent patients - Industry credibility and liability protection

---

Pre-Launch Timeline

| Timeline | Action | Owner | |---|---|---| | Week 1 | Finalize pharmacy partnership agreement | Operations | | Week 2 | Update consent forms with legal review | Legal/Medical Director | | Week 3 | Staff training on protocols, documentation, marketing compliance | Operations/Clinical | | Week 4 | Patient screening and scheduling | Front desk/Medical Director | | Week 5 | First patient appointments begin | Clinical team |

---

Ready to Reactivate?

Apply for GlowRoute Peptide Clinic Verification →^[1]

---

Additional Resources

• FDA Compounding Pharmacy Registry^[2]
• GlowRoute Consent Form Templates^[3]
• State Medical Board Delegation Requirements^[4]
• Peptide Clinic Documentation Toolkit^[5]

---

Legal Disclaimer: This checklist provides general guidance and is not legal advice. Regulations vary significantly by state. Before restarting peptide programs, consult with: 1. Your state medical board 2. A healthcare attorney in your state 3. Your malpractice insurance provider 4. Your compounding pharmacy legal team

Each jurisdiction has unique requirements. Some states may have additional restrictions not covered here. Regulatory status of compounded peptides continues to evolve. This article reflects information accurate as of April 2026.

Last Updated: April 4, 2026